Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo

This article was originally published in The Gray Sheet

Executive Summary

Following simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.

You may also be interested in...

News Briefs: Siemens-Pfizer Dx Pact; Pancreatic Stent; AtriCure Acquisition

Siemens teams with Pfizer on companion Dx. XLumena gains pancreatic stent approval. AtriCure acquires Estech. More news.

News In Brief

Roche’s melanoma companion diagnostic approved

FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail

FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts